Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression

被引：422
作者：
Bangsberg, David R.
机构：
[1] Univ Calif San Francisco, Epidemiol & Prevent Intervent Ctr, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, San Francisco Gen Hosp, Epidemiol & Prevent Intervent Ctr, Div Infect Dis, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, San Francisco Gen Hosp, Epidemiol & Prevent Intervent Ctr, Posit Hlth Program, San Francisco, CA 94143 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2006年 / 43卷 / 07期
关键词：
D O I：
10.1086/507526
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
For antiretroviral therapy, the 95% adherence "threshold" is based on nucloside- exposed patients who are receiving partially suppressive, unboosted protease inhibitor regimens. Using unannounced pill counts and electronic medication monitoring, viral suppression is common with a 54% - 100% mean adherence level to nonnucleoside reverse-transcriptase-inhibitor regimens. Although perfect adherence is an important goal, viral suppression is possible with moderate adherence to potent regimens.
引用
收藏
页码：939 / 941
页数：3
相关论文
共 18 条
[1]   Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring [J].
Arnsten, JH ;
Demas, PA ;
Farzadegan, H ;
Grant, RW ;
Gourevitch, MN ;
Chang, CJ ;
Buono, D ;
Eckholdt, H ;
Howard, AA ;
Schoenbaum, EE .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1417-1423
[2]   Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness [J].
Bangsberg, DR ;
Acosta, EP ;
Gupta, R ;
Guzman, D ;
Riley, ED ;
Harrigan, PR ;
Parkin, N ;
Deeks, SG .
AIDS, 2006, 20 (02) :223-231
[3]   High levels of adherence do not prevent accumulation of HIV drug resistance mutations [J].
Bangsberg, DR ;
Charlebois, ED ;
Grant, RM ;
Holodniy, M ;
Deeks, SG ;
Perry, S ;
Conroy, KN ;
Clark, R ;
Guzman, D ;
Zolopa, A ;
Moss, A .
AIDS, 2003, 17 (13) :1925-1932
[4]   Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population [J].
Bangsberg, DR ;
Hecht, FM ;
Charlebois, ED ;
Zolopa, AR ;
Holodniy, M ;
Sheiner, L ;
Bamberger, JD ;
Chesney, MA ;
Moss, A .
AIDS, 2000, 14 (04) :357-366
[5]   Is average adherence to HIV antiretroviral therapy enough? [J].
Bangsberg, DR ;
Deeks, SG .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2002, 17 (10) :812-813
[6]   Non-adherence to highly active antiretroviral therapy predicts progression to AIDS [J].
Bangsberg, DR ;
Perry, S ;
Charlebois, ED ;
Clark, RA ;
Roberston, M ;
Zolopa, AR ;
Moss, A .
AIDS, 2001, 15 (09) :1181-1183
[7]  
de Olalla PG, 2002, J ACQ IMMUN DEF SYND, V30, P105, DOI 10.1097/00042560-200205010-00014
[8]   Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy [J].
Harrigan, PR ;
Hogg, RS ;
Dong, WWY ;
Yip, B ;
Wynhoven, B ;
Woodward, J ;
Brumme, CJ ;
Brumme, ZL ;
Mo, T ;
Alexander, CS ;
Montaner, JSG .
JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (03) :339-347
[9]   Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up [J].
Hogg, RS ;
Heath, K ;
Bangsberg, D ;
Yip, B ;
Press, N ;
O'Shaughnessy, MV ;
Montaner, JSG .
AIDS, 2002, 16 (07) :1051-1058
[10]   Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors [J].
Maggiolo, F ;
Ravasio, L ;
Ripamonti, D ;
Gregis, G ;
Quinzan, G ;
Arici, C ;
Airoldi, M ;
Suter, F .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (01) :158-163
12